The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease
Abstract
Background & aims Around 10-20% of patients with non-alcoholic fatty liver disease (NAFLD) are non-obese. The benefit of weight reduction in such patients is unclear. We aim to study the efficacy of lifestyle intervention in non-obese patients with NAFLD and to identify factors that predict treatment response.Methods A total of 154 community NAFLD patients were randomised to a 12-month lifestyle intervention programme involving regular exercise, or to standard care. The primary outcome was remission of NAFLD at Month 12 by proton-magnetic resonance spectroscopy. After the programme, the patients were prospectively followed until Year 6. The Asian body mass index (BMI) cut-off of 25 kg/m 2 was used to define non-obese NAFLD.Results Patients were assigned to the intervention (n = 77) and control (n = 77) groups (39 and 38 in each group had baseline BMI <25 and ≥25 kg/m 2, respectively). More patients in the intervention group achieved the primary outcome than the control group regardless of baseline BMI (non-obese: 67% vs. 18%, p <0.001; obese: 61% vs. 21%, p <0.001). Lifestyle intervention, lower baseline intrahepatic triglyceride, and reduction in body weight and waist circumference were independent factors associated with remission of NAFLD in non-obese patients. Half of non-obese patients achieved remission of NAFLD with 3-5% weight reduction; the same could only be achieved in obese patients with 7-10% weight reduction. By Year 6, non-obese patients in the intervention group remained more likely to maintain weight reduction and alanine aminotransferase normalisation than the control group.Conclusions Lifestyle intervention is effective in treating NAFLD in both non-obese and obese patients. Weight reduction predicts remission of NAFLD in non-obese patients, but a modest weight reduction may be sufficient in this population.Lay summary Some patients with non-alcoholic fatty liver disease (NAFLD) are non-obese. The optimal management of such patients is unclear. In this long-term follow-up study of a clinical trial, we show that remission of NAFLD can be achieved in 67% of non-obese patients after lifestyle intervention. The majority of patients can achieve NAFLD remission with modest weight loss of 3-10%. Non-obese patients are also more likely than obese patients to maintain weight reduction and normal liver enzymes in the long run.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In an RCT of a 12month lifestyle intervention programme, a 3-5% weight reduction led to remission of MASLD (measured by 1 H-MRS) among 50% of the individuals without obesity.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [333]
In the citing paper
“Moreover, individuals de fi ned as non-obese were more likely than individuals with obesity to maintain weight reduction and normal liver enzymes over long-term (6-year) follow-up. 333”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [333]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,146
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Long-term weight loss maintenance
Wing, R. R., & Phelan, S. (2005) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/82.1.222s · Cited by 1,941
Franz, M. J., VanWormer, J. J., Crain, A. L., Boucher, J. L., Histon, T., Caplan, W., Bowman, J. D., & Pronk, N. P. (2007) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.07.017 · Cited by 1,559
Treatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
Promrat, K., Kleiner, D. E., Niemeier, H. M., Jackvony, E., Kearns, M., Wands, J. R., Fava, J. L., & Wing, R. R. (2010) · Hepatology · doi:10.1002/hep.23276 · Cited by 1,330
Wong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, H. L.-Y., Le Bail, B., Choi, P. C.-L., Kowo, M., Chan, A. W.-H., Merrouche, W., et al. (2010) · Hepatology · doi:10.1002/hep.23312 · Cited by 1,322
New trends on obesity and NAFLD in Asia
Fan, J.-G., Kim, S. U., & Wong, V. W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.003 · Cited by 1,100
Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024
Petersen, K. F., Dufour, S., Befroy, D., Lehrke, M., Hendler, R. E., & Shulman, G. I. (2005) · Diabetes · doi:10.2337/diabetes.54.3.603 · Cited by 911
Nonalcoholic fatty liver disease
Brunt, E. M., Wong, V. W., Nobili, V., Day, C. P., Sookoian, S. C., Maher, J. J., Bugianesi, E., Sirlin, C. B., Neuschwander‐Tetri, B. A., & Rinella, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.80 · Cited by 889
Ryan, M. C., Itsiopoulos, C., Thodis, T., Ward, G., Trost, N., Hofferberth, S., O’Dea, K., Desmond, P. V., Johnson, N. A., & Wilson, A. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.012 · Cited by 778
Thoma, C., Day, C. P., & Trenell, M. I. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.06.010 · Cited by 523
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: a systematic review
Hashida, R., Kawaguchi, T., Bekki, M., Omoto, M., Matsuse, H., Nago, T., Takano, Y., Ueno, T., Koga, H., George, J., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.023 · Cited by 509
Wong, V. W., Chu, C. W., Wong, G. L., Chan, R., Chim, A. M., Ong, A., Yeung, D. K., Yiu, K. K., Chu, S. H.-T., Woo, J., et al. (2011) · Gut · doi:10.1136/gutjnl-2011-300342 · Cited by 491
Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease
Nobili, V., Manco, M., Vito, R. D., Ciommo, V. M. D., Comparcola, D., Sartorelli, M. R., Piemonte, F., Marcellini, M., & Angulo, P. (2008) · Hepatology · doi:10.1002/hep.22336 · Cited by 412
Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients
Leung, J. C., Loong, T. C., Wei, J. L., Wong, G. L., Chan, A. W. H., Choi, P. C., Shu, S. S., Chim, A. M., Chan, H. L., & Wong, V. W. (2016) · Hepatology · doi:10.1002/hep.28697 · Cited by 348
Wong, V. W., Chan, R., Wong, G. L., Cheung, B., Chu, C. W., Yeung, D. K., Chim, A. M., Lai, J. W.-Y., Li, L. S., Sea, M. M.-M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.013 · Cited by 346
Kim, D., & Kim, W. R. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.08.028 · Cited by 341
Wei, J. L., Leung, J. C., Loong, T. C., Wong, G. L., Yeung, D. K., Chan, R., Chan, H. L., Chim, A. M., Woo, J., Chu, C. W., et al. (2015) · The American Journal of Gastroenterology · doi:10.1038/ajg.2015.235 · Cited by 317
Sullivan, S. A., Kirk, E. P., Mittendorfer, B., Patterson, B. W., & Klein, S. (2011) · Hepatology · doi:10.1002/hep.25548 · Cited by 313
Haufe, S., Engeli, S., Kast, P., Böhnke, J., Utz, W., Haas, V., Hermsdorf, M., Mähler, A., Wiesner, S., Birkenfeld, A. L., et al. (2011) · Hepatology · doi:10.1002/hep.24242 · Cited by 307
High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis
Wong, V. W., Wong, G. L., Tsang, S. W., Fan, T., Chu, C. W., Woo, J., Chan, A. W. H., Choi, P. C. L., Chim, A. M.-L., Lau, J. Y. W., et al. (2011) · Gut · doi:10.1136/gut.2011.237974 · Cited by 257
Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver
Feldman, A., Eder, S. K., Felder, T. K., Kedenko, L., Paulweber, B., Stadlmayr, A., Huber-Schönauer, U., Niederseer, D., Stickel, F., Auer, S., et al. (2016) · The American Journal of Gastroenterology · doi:10.1038/ajg.2016.318 · Cited by 240
Sookoian, S., & Pirola, C. J. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14112 · Cited by 230
Bozzetto, L., Prinster, A., Annuzzi, G., Costagliola, L., Mangione, A., Vitelli, A., Mazzarella, R., Longobardo, M., Mancini, M., Vigorito, C., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0033 · Cited by 227
Normal weight individuals who develop Type 2 diabetes: the personal fat threshold
Taylor, R., & Holman, R. R. (2014) · Clinical Science · doi:10.1042/cs20140553 · Cited by 201
Wong, V. W., Wong, G. L., Yeung, D. K., Lau, T. K., Chan, C. K.-M., Chim, A. M., Abrigo, J., Chan, R., Woo, J., Tse, Y., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.041 · Cited by 173
George, A. S., Bauman, A. E., Johnston, A., Farrell, G. C., Chey, T., & George, J. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05694.x · Cited by 117
Sookoian, S. C., & Pirola, C. J. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14401 · Cited by 103
Wong, V. W., Hui, A., Tsang, S. W., Chan, J. L.-Y., Wong, G. L., Chan, A. W. H., So, W., CHENG, A. Y. S., Tong, P. C. Y., Chan, F. K. L., et al. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03112.x · Cited by 92
de Luis, D. A., Aller, R., Izaola, O., Sagrado, M. G., & Conde, R. (2010) · PubMed · Cited by 70
Cited by
Sorted by citations
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
Aron‐Wisnewsky, J., Vigliotti, C., Witjes, J. J., Le, P. T., Holleboom, A. G., Verheij, J., Nieuwdorp, M., & Clément, K. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0269-9 · Cited by 1,132
Eslam, M., Sarin, S. K., Wong, V. W., Fan, J.-G., Kawaguchi, T., Ahn, S. H., Zheng, M., Shiha, G. E.-S., Yilmaz, Y. N., Gani, R. A., et al. (2020) · Hepatology International · doi:10.1007/s12072-020-10094-2 · Cited by 860
Younossi, Z. M., Corey, K. E., & Lim, J. K. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.11.051 · Cited by 510
Metadata
- Authors
- Wong, V. W.-S., Wong, G. L.-H., Chan, R. S.-M., Shu, S. S.-T., Cheung, B. H.-K., Li, L. S., Chim, A. M.-L., Chan, C. K.-M., Leung, J. K.-Y., Chu, W. C.-W., Woo, J., & Chan, H. L.-Y.
- Affiliations
- Chinese University of Hong Kong (HK)
- Corresponding author
- Chan, Henry Lik-Yuen
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 69
- Issue
- 6
- Pages
- 1349-1356
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2888552653
- Cited by
- 319
- References
- 35
- Citations by year
- 2026: 27 · 2025: 39 · 2024: 62 · 2023: 54 · 2022: 40 · 2021: 45 · 2020: 31 · 2019: 18 · 2018: 1
- FWCI
- 18.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, non-obese patients, lifestyle intervention, physical activity, weight loss, intrahepatic triglyceride, waist circumference, predictors of treatment response, community-based patients, long-term follow-up, weight maintenance, 1H NMR
- MeSH terms
- Adult, Aged, Diet, Female, Follow-Up Studies, Humans, Life Style, Male, Middle Aged, Obesity, Prospective Studies, Remission Induction, Triglycerides, Weight Loss, Exercise, Body Mass Index, Single-Blind Method, Treatment Outcome, Waist Circumference, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review